EMA/170135/2019

European Medicines Agency decision

P/0112/2019

of 22 March 2019

on the acceptance of a modification of an agreed paediatric investigation plan and on granting of a waiver in condition for treatment of soft tissue sarcoma for olaratumab (Lartruvo), (EMEA-001760-PIP01-15-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0112/2019

of 22 March 2019

on the acceptance of a modification of an agreed paediatric investigation plan and on granting of a waiver in condition for treatment of soft tissue sarcoma for olaratumab (Lartruvo), (EMEA-001760-PIP01-15-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0290/2015 issued on 27 November 2015, the decision P/0299/2016 issued on 4 November 2016 and the decision P/0139/2017 issued on 7 June 2017,

Having regard to the application submitted by Eli Lilly and Company Limited on 26 October 2018 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 1 February 2019, in accordance with Article 22 of Regulation (EC) No 1901/2006 and of its own motion in accordance with Article 12 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

(3) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for olaratumab (Lartruvo), concentrate for solution for infusion, intravenous use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

A product specific waiver for olaratumab (Lartruvo), concentrate for solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Eli Lilly and Company Limited, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, GU206PH - Windlesham, United Kingdom.

EMA/PDCO/798093/2018
London, 1 February 2019

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan and on the granting of a product-specific waiver

EMEA-001760-PIP01-15-M03

Scope of the application

Active substance(s):

Olaratumab

Invented name:

Lartruvo

Condition(s):

Treatment of osteosarcoma

Treatment of soft tissue sarcoma

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Concentrate for solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Eli Lilly and Company Limited

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Eli Lilly and Company Limited submitted to the European Medicines Agency on 26 October 2018 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0290/2015 issued on 27 November 2015, the decision P/0299/2016 issued on 4 November 2016 and the decision P/0139/2017 issued on 7 June 2017.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 4 December 2018.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

A waiver has been added.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion;
   - to grant a waiver for one or more subsets of the paediatric population on its own motion in accordance with Article 12 of said Regulation and concluded in accordance with Article 11(1)(c) of Regulation (EC) No 1901/2006 as amended, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of osteosarcoma

The waiver applies to:

- the paediatric population from birth to less than 5 years of age;
- concentrate for solution for infusion, for intravenous use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

1.2. Condition

Treatment of soft tissue sarcoma

The waiver applies to:

- the paediatric population from birth to less than 18 years of age;
- concentrate for solution for infusion, for intravenous use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition

Treatment of osteosarcoma

2.1.1. Indication(s) targeted by the PIP

Treatment in monotherapy of paediatric patients from 5 to less than 18 years of age with recurrent osteosarcoma limited to resected pulmonary metastases.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 5 years to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Concentrate for solution for infusion

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable.

Non-clinical studies	3	**Study 1** Pilot juvenile non-clinical study to support use of olaratumab in paediatric patients of less than 4 years of age. **Study 2** In vivo non-clinical efficacy study. **Study 6 (added in this modification)** Definitive juvenile non-clinical study to support use of olarutumab in paediatric patients of less than 4 years of age.
Clinical studies	2	**Study 3** Open-label, multi-centre, multiple-dose trial to investigate the pharmacokinetics, toxicity and safety and to observe any anti-tumour activity of olaratumab as single agent and as add-on to anti-cancer medicines in paediatric patients from birth to less than 18 years of age with a solid malignant tumour **Study 4** Multi-centre, randomised, open-label controlled, study to evaluate safety and efficacy of olaratumab monotherapy in paediatric patients from 5 years to less than 18 years (and adults) with osteosarcoma limited to resected pulmonary metastases
Extrapolation, modelling and simulation studies	1	**Study 5** Paediatric population pharmacokinetic analysis
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2024
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of soft tissue sarcoma

Authorised indication(s):

- Lartruvo is indicated in combination with doxorubicin for the treatment of adult patients with advanced soft tissue sarcoma who are not amenable to curative treatment with surgery or radiotherapy and who have not been previously treated with doxorubicin.

Authorised pharmaceutical form(s):

Concentrate for solution for infusion

Authorised route(s) of administration:

Intravenous use